Progress and prospects: Biological properties and technological advances of herpes simplex virus type 1-based amplicon vectors

Gene Therapy

Volumn 16, Issue 6, 2009, Pages 709-715

  Epstein, A L ^a,b,c  

^a UNIVERSITÉ DE LYON   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE DE GÉNÉTIQUE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FRATAXIN; GONADORELIN; HYPOXANTHINE PHOSPHORIBOSYLTRANSFERASE; INTERFERON REGULATORY FACTOR 3; PLASMID VECTOR; STAT1 PROTEIN; VIRUS VECTOR;

AMPLICON; ARTIFICIAL CHROMOSOME; CELL CYCLE REGULATION; CELL TYPE; DRUG SCREENING; EPISOME; GENE CASSETTE; GENE EXPRESSION REGULATION; GENE REPLICATION; GENE SILENCING; GENE TECHNOLOGY; GENETIC TRANSDUCTION; GENOMIC INSTABILITY; HERPES SIMPLEX VIRUS 1; HUMAN; MATRIX ATTACHMENT REGION; MOLECULAR IMAGING; NON INVASIVE PROCEDURE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STEM CELL GENE THERAPY; TISSUE SPECIFICITY; TRANSGENE; TRANSPOSON; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIRUS CELL INTERACTION;

HUMAN HERPESVIRUS 1;

EID: 67349166164     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.42     Document Type: Review

References (33)

1. Cuchet D, Potel C, Thomas J, Epstein AL. HSV-1 amplicon vectors: A promising and versatile tool for gene delivery. Expert Opin Biol Ther 2007; 7: 975-995.
2. Suzuki M, Chiocca EA, Saeki Y. Early STAT1 activation after systemic delivery of HSV amplicon vectors suppresses transcription of the vector-encoded transgene. Mol Ther 2007; 15: 2017-2026.
3. Suzuki M, Chiocca EA, Saeki Y. Stable transgene expression from HSV amplicon vectors in the brain: Potential involvement of immunoregulatory signals. Mol Ther 2008; 16: 1727-1736.
4. Tsitoura E, Epstein AL Personal communication. Preliminary results were presented at the 31th International Herpesvirus Workshop, Seattle, WA, USA (2006) and at the 14th Meeting of the European Society of Gene Therapy, Athens, Greece (2006).
5. Everett RD, Rechter S, Papior P, Tavalai N, Stamminger T, Orr A et al PML contributes to a cellular mechanism of repression of herpes simplex virus type 1 infection that is inactivated by ICP0. J Virol 2006; 80: 7995-8005.
6. Suzuki M, Kasai K, Saeki Y. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 2006; 80: 3293-3300.
7. Burris CA, de Silva S, Narrow WC, Casey AE, Lotta Jr LT, Federoff HJ et al. Hexamethylene bisacetamide leads to reduced helper virus-free HSV-1 amplicon expression titers via suppression of ICP0. J Gene Med 2008; 10: 152-164.
8. Rasmussen M, Kong L, Zhang GR, Liu M,Wang X, Szabo G et al. Glutamatergic or GABAergic neuron-specific, long-term expression in neocortical neurons from helper virus-free HSV-1 vectors containing the phosphate-activated glutaminase, vesicular glutamate transporter-1, or glutamic acid decarboxylase promoter. Brain Res 2007; 1144: 19-32.
9. Jeong KH, Bakowska JC, Song IO, Fu N, Breakefield XO, Kaiser UB. Improvement in reproductive parameters in hypogonadal female mice by regulated gene replacement therapy in the central nervous system. Gene Therapy 2007; 14: 1092-1101.
10. Gomez-Sebastian S, Gimenez-Cassina A, Diaz-Nido J, Lim F, Wade-Martins R. Infectious delivery and expression of a 135 kb human FRDA genomic DNA locus complements Friedreich's ataxia deficiency in human cells. Mol Ther 2007; 15: 248-254.
11. Ho IA, Hui KM, Lam PY. Targeting proliferating tumor cells via the transcriptional control of therapeutic genes. Cancer Gene Ther 2006; 13: 44-52.
12. Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA et al. An efficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther 2007; 15: 1129-1136.
13. Wang GY, Ho IA, Sia KC, Miao L, Hui KM, Lam PY. Engineering an improved cell cycle-regulatable herpes simplex virus type 1 amplicon vector with enhanced transgene expression in proliferating cells yet attenuated activities in resting cells. Hum Gene Ther 2007; 18: 222-231.
14. Glauser DL, Ackermann M, Saydam O, Fraefel C. Chimeric herpes simplex virus/adeno-associated virus amplicon vectors. Curr Gene Ther 2006; 6: 315-324.
15. Liu Q, Perez CF, Wang Y. Efficient site-specific integration of large transgenes by an enhanced herpes simplex virus/adeno-associated virus hybrid amplicon vector. J Virol 2006; 80: 1672-1679.
16. Oehmig A, Cortés ML, Perry KF, Sena-Esteves M, Fraefel C, Breakefield XO. Integration of active human beta-galactosidase gene (100 kb) into genome using HSV/AAV amplicon vector. Gene Therapy 2007; 14: 1078-1091.
17. Cortes ML, Oehmig A, Perry KF, Sanford JD, Breakefield XO. Expression of human ATM cDNA in Atm-deficient mouse brain mediated by HSV-1 amplicon vector. Neuroscience 2006; 141: 1247-1256.
18. Cortés ML, Oehmig A, Saydam O, Sanford JD, Perry KF, Fraeferl C et al. Targeted integration of functional human ATM cDNA into genome mediated by HSV/AAV hybrid amplicon vector. Mol Ther 2008; 16 81-88.
19. Bowers WJ, Mastrangelo MA, Howard DF, Southerland HA, Maguire-Zeiss KA, Federoff HJ. Neuronal precursor-restricted transduction via in utero CNS gene delivery of a novel bipartite HSV amplicon/transposase hybrid vector. Mol Ther 2006; 13: 580-588.
20. Peterson EB, Mastrangelo MA, Federoff HJ, Bowers WJ. Neuronal specificity of HSV/sleeping beauty amplicon transduction in utero is driven primarily by tropism and cell type composition. Mol Ther 2007; 15: 1848-1855.
21. Lufino MM, Edser PA, Wade-Martins R. Advances in high-capacity extrachromosomal vector technology: Episomal maintenance, vector delivery, and transgene expression. Mol Ther 2008; 16: 1525-1538.
22. Lufino MM, Manservigi R, Wade-Martins R. An S/MAR-based infectious episomal genomic DNA expression vector provides long-term regulated functional complementation of LDLR deficiency. Nucleic Acids Res 2007; 35: E98.
23. Moralli D, Simpson KM, Wade-Martins R, Monaco ZL. A novel human artificial chromosome gene expression system using herpes simplex virus type 1 vectors. EMBO Rep 2006; 7: 911-918.
24. Riethmacher D, Lim F, Schimmang T. Efficient transfer of HSV-1 amplicon vectors into embryonic stem cells and their derivatives. Methods Mol Biol 2006; 329: 265-272.
25. Ho IA, Chan KY, Miao L, Shim WS, Guo CM, Cheang P et al. HSV-1 amplicon viral vector-mediated gene transfer to human bone marrow-derived mesenchymal stem cells. Cancer Gene Ther 2008; 15: 553-562.
26. Tyler CM, Wuertzer CA, Bowers WJ, Federoff HJ. HSV amplicons: Neuro applications. Curr Gene Ther 2006; 6: 337-350.
27. Shah K, Breakefield XO. HSV amplicon vectors for cancer therapy. Curr Gene Ther 2006; 6: 361-370.
28. Jerusalinsky D, Epstein AL. Amplicon vectors as outstanding tools to study and modify cognitive functions. Curr Gene Ther 2006; 6 351-360.
29. Tsitoura E, Georgopoulou U, Mavromara P. HSV-1 based amplicon vectors as an alternative system for the expression of functional HCV proteins. Curr Gene Ther 2006; 6: 393-398.
30. Santos K, Duke CMP, Dewhurst S. Amplicon vectors as Vaccine vectors. Curr Gene Ther 2006; 6: 383-392.
31. Winkeler A, Sena-Esteves M, Paulis LE, Li H, Waerzeggers Y, Rückriem B et al. Switching on the lights for gene therapy. PLoS ONE 2007; 2: E528.
32. Kummer C, Winkeler A, Dittmar C, Bauer B, Rueger MA, Rueckriem B et al. Multitracer positron emission tomographic imaging of exogenous gene expression mediated by a universal herpes simplex virus 1 amplicon vector. Mol Imaging 2007; 6: 181-192.
33. Pike L, Petravicz J, Wang S. Bioluminescence imaging after HSV amplicon vector delivery into brain. J Gene Med 2006; 8: 804-813.